The price of a Gilead Sciences (GILD) pill approved in the U.S. last fall to prevent HIV would have to be cut nearly in half in order to be cost-effective because it has questionable benefits over an older, similar pill that will face lower-cost generic competition later this year, according to a new analysis.
As a result, the authors argued that switching to the newer medicine might limit access and boost HIV transmission. For its part, the drug maker shot back the methodology used in the study was “flawed” and led to “inaccurate conclusions that severely underestimate the value” of the newer medicine.
It seems Gilead clearly did not approach Rochelle P. Walensky and ask whether she would be willing to serve a consultant for the company and if so, for how much!
I guess not.
ed at pharmalot
Comments are closed.